baseclick GmbH secures revolutionary U.S. Patent for Click modified mRNA Technology
Development of innovative platform enhances mRNA therapeutics with improved stability, targeting and delivery
Neuried, Germany (June 06, 2025) baseclick GmbH, a leader in nucleic acid chemistry and bioorthogonal labeling technologies, is proud to announce the issuance of U.S. Patent No. 12,257,267 B2, entitled “Click-Modified mRNA.” This newly granted patent protects baseclick’s pioneering technology for chemically modified messenger RNA (mRNA) significantly improves the performance and clinical utility of mRNA-based therapeutics.
The patent covers all novel classes of alkyne and/or azide-modified mRNAs that are seamlessly integrated with click chemistry, which is a modular, highly specific approach for nucleic acid bioconjugation. This innovation enables the precise attachment of functional molecules such as fluorescent labels, targeting ligands or delivery enhancers to mRNA strands, opening the door to next-generation RNA-based treatments for cancer, infectious diseases and genetic disorders.
Key Features of Patented Technology:
- Enhanced mRNA stability and translation efficiency via chemical modifications in the 5’-UTR, ORF, 3’-UTR, or poly(A) tail
- Click-enabled conjugation for targeted cell delivery, real-time tracking, or therapeutic customization
- Compatibility with ex vivo and in vivo delivery strategies, including lipid nanoparticle (LNP) formulations
- Support for immune cell transfection, enabling personalized immunotherapies and vaccines
“This patent reflects baseclick’s ongoing commitment to shaping the future of molecular medicine,” said Dr. Thomas Frischmuth, Managing Director and inventor. “Our click-modified mRNA platform not only enables safer and more efficient therapies but also empowers researchers and clinicians with a flexible tool to track, target, and tailor mRNA therapeutics like never before.”
The issuance of this patent comes at a pivotal time for RNA science, as the global biopharmaceutical industry increasingly embraces mRNA for vaccines, gene therapies, and regenerative medicine. baseclick’s proprietary approach offers a new level of control and functionalization, solving key challenges in stability, delivery, and precision targeting.
baseclick GmbH welcomes inquiries for research collaborations, technology licensing, and clinical partnerships to accelerate the development and commercialization of click-modified mRNA therapies.
About baseclick GmbH
baseclick GmbH, based in Neuried, Germany, is a biotechnology company specializing in nucleic acid chemistry, click chemistry, and bioconjugation technologies. Since its founding in 2008, baseclick has been at the forefront of innovation in molecular labeling and RNA modification, enabling advances in diagnostics, therapeutics, and life sciences research.
Contact:
baseclick GmbH
Floriansbogen 2-4
82061 Neuried (Munich)
Germany
Phone: +49 89 9699 3401
Email: info@baseclick.eu
Website: www.baseclick.eu